The therapy app for more air and health

Informacje na temat projektu

KATA

Identyfikator umowy o grant: 867249

DOI

10.3030/867249

Projekt został zamknięty

Data podpisania przez KE 23 Kwietnia 2019

Data rozpoczęcia 1 Maja 2019

Data zakończenia 31 Sierpnia 2019

Finansowanie w ramach

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Koszt całkowity

€ 71 429,00

Wkład UE

€ 50 000,00

Koordynowany przez

VISIONHEALTH GMBH
Germany

Periodic Reporting for period 1 - KATA (The therapy app for more air and health)

Okres sprawozdawczy: 2019-05-01 do 2019-08-31

Podsumowanie kontekstu i ogólnych celów projektu

Chronic respiratory diseases (CRDs), such as chronic obstructive pulmonary disease (COPD) and asthma, are the world’s fourth major health problem with 600 million people according to the World Health Organization (WHO). However, given the current number of cases, persistent smoking, aging population and the increasing levels of pollution in emerging countries, CRDs will become the third leading cause of death in the EU by 2030. Although CRDs patients are mostly treated with different inhalation devices, 90% of them are not using properly their inhalers which is essential to prevent exacerbations and decrease hospitalization and ED visits

Kata® app solution enhances inhalation therapy and trains CRDs patients with asthma or COPD to use their inhalers effectively, to improve their quality of life. The company behind Kata is VisionHealth, specialized in digital healthcare. Our mission consists in providing disruptive digital healthcare solutions for patients, to benefit from the full potential of their respiratory care. Our final goal is for respiratory patients to be liberated from their symptoms, enjoying life to the fullest and needing the healthcare system least.

Prace wykonane od początku projektu do końca okresu sprawozdawczego oraz najważniejsze dotychczasowe rezultaty

From a technical point of view, we have defined the technical process and optimization to evolve from a knowledge-based algorithm to a supervised machine learning driven approach in order to increase detection accuracy, while optimizing performance and usability of the software. We have elaborated a complete Execution Plan with a risk analysis and mitigation measures. Commercially, we have performed an analysis of our target markets, updated our business and revenue streams, and also consolidated our dissemination and commercial strategy. We have updated our Freedom-to-Operate analysis and a based line scenario and financial forecast has been drafted to evaluate a five year projection.

Innowacyjność oraz oczekiwany potencjalny wpływ (w tym dotychczasowe znaczenie społeczno-gospodarcze i szersze implikacje społeczne projektu)

CRDs are a huge economic burden comprising 78% of total direct healthcare costs associated to respiratory diseases in the EU. The annual costs of healthcare and lost productivity due to COPD are estimated as €48.4 billion and those due to asthma reach €33.9 billion euros. The global mHealth market is expected to reach €97B by 2025, growing at a CAGR of 44.2% with Europe and Asia Pacific leading the market.

Kata® will contribute to improve European and worldwide CRDs patient quality of life while reducing the economic burden and healthcare cost and increase working hours and productivity of patients. In addition, it will contribute to strengthen the leading position of Europe in the global mobile medical apps market.

image-1.png